DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/kznsd3/francisella)
has announced the addition of Global Markets Direct's new report "Francisella
Tularensis Infections - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline
Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic
development for Francisella Tularensis Infections, complete with latest
updates, and special features on late-stage and discontinued projects.
It also reviews key players involved in the therapeutic development for
Francisella Tularensis Infections. Francisella Tularensis Infections -
Pipeline Review, Half Year is built using data and information sourced
from Global Markets Direct's proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Scope
-
A snapshot of the global therapeutic scenario for Francisella
Tularensis Infections.
-
A review of the Francisella Tularensis Infections products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
-
Coverage of products based on various stages of development ranging
from discovery till registration stages.
-
A feature on pipeline projects on the basis of monotherapy and
combined therapeutics.
-
Coverage of the Francisella Tularensis Infections pipeline on the
basis of route of administration and molecule type.
-
Key discontinued pipeline projects.
-
Latest news and deals relating to the products.
Reasons to buy
-
Identify and understand important and diverse types of therapeutics
under development for Francisella Tularensis Infections.
-
Identify emerging players with potentially strong product portfolio
and design effective counter-strategies to gain competitive advantage.
-
Plan mergers and acquisitions effectively by identifying players of
the most promising pipeline.
-
Devise corrective measures for pipeline projects by understanding
Francisella Tularensis Infections pipeline depth and focus of
Indication therapeutics.
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/kznsd3/francisella
Source: Global Markets Direct
